Ad
ADAP Short Information Adaptimmune Therapeutics plc
home / stock / adap / adap short
Short Information | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 7,821,119 |
| Total Actual Volume | 51,411,951 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 391,056 |
| Average Short Percentage | 16.59% |
Is there a ADAP Short Squeeze or Breakout about to happen?
See the ADAP Short Analysis for free Sign up or Login
Powered by Squeeze Report
ADAP Twenty Trading Day's Volume to Short Volume Chart
ADAP Twenty Trading Day Price Chart
ADAP Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 01-14-2025 | $0.649 | $0.5899 | $0.649 | $0.576 | 1,016,401 | 310,577 | 30.56% |
| 01-13-2025 | $0.6151 | $0.5953 | $0.63 | $0.5753 | 1,608,299 | 432,497 | 26.89% |
| 01-10-2025 | $0.619 | $0.62 | $0.6265 | $0.575 | 1,799,143 | 409,760 | 22.78% |
| 01-08-2025 | $0.65 | $0.6199 | $0.65 | $0.59 | 1,457,326 | 367,654 | 25.23% |
| 01-07-2025 | $0.66 | $0.6543 | $0.67 | $0.6 | 2,142,038 | 577,368 | 26.95% |
| 01-06-2025 | $0.6491 | $0.65 | $0.685 | $0.645 | 1,052,442 | 263,746 | 25.06% |
| 01-03-2025 | $0.62 | $0.6491 | $0.675 | $0.62 | 2,791,205 | 374,534 | 13.42% |
| 01-02-2025 | $0.5438 | $0.6235 | $0.6615 | $0.5438 | 2,362,134 | 329,779 | 13.96% |
| 12-31-2024 | $0.5501 | $0.5387 | $0.5619 | $0.5316 | 3,231,469 | 412,390 | 12.76% |
| 12-30-2024 | $0.58 | $0.554 | $0.5882 | $0.554 | 3,814,374 | 635,074 | 16.65% |
| 12-27-2024 | $0.56 | $0.59 | $0.6078 | $0.5571 | 4,799,211 | 654,035 | 13.63% |
| 12-26-2024 | $0.575 | $0.5677 | $0.5878 | $0.5473 | 4,660,286 | 722,388 | 15.5% |
| 12-24-2024 | $0.581 | $0.5788 | $0.59 | $0.5751 | 1,198,355 | 141,401 | 11.8% |
| 12-23-2024 | $0.5966 | $0.588 | $0.605 | $0.5792 | 2,451,861 | 292,695 | 11.94% |
| 12-20-2024 | $0.6 | $0.6049 | $0.605 | $0.5864 | 3,097,884 | 205,735 | 6.64% |
| 12-19-2024 | $0.6 | $0.6 | $0.62 | $0.5836 | 2,376,083 | 187,842 | 7.91% |
| 12-18-2024 | $0.6 | $0.606 | $0.6329 | $0.59 | 3,269,657 | 632,278 | 19.34% |
| 12-17-2024 | $0.58 | $0.5994 | $0.6133 | $0.5701 | 2,622,768 | 286,316 | 10.92% |
| 12-16-2024 | $0.5764 | $0.5914 | $0.6048 | $0.572 | 2,626,884 | 118,348 | 4.51% |
| 12-13-2024 | $0.6012 | $0.5801 | $0.6154 | $0.5511 | 3,034,131 | 466,702 | 15.38% |
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Ad
-
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Ph...
-
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsf...
-
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the t...